(vianews) - shares of innate pharma (cac 40: iph.pa) jumped by a staggering 16.33% in 5 sessions from €2.68 to €3.12 at 11:53 est on thursday, following the last session's downward trend. cac 40 is rising 0.96% to €7,468.27, after three consecutive sessions in a row of gains.
about innate pharma
innate pharma s.a., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in france and internationally. the company's products include lacutamab (iph4102), an anti-kir3dl2 antibody, which is in phase ii clinical trials for the treatment of cutaneous t-cell and peripheral t-cell lymphoma, as well as in phase ii clinical trials to treat refractory sézary syndrome; monalizumab, an immune checkpoint inhibitor that is in phase iii clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; avdoralimab (iph5401), a monoclonal antibody blocking c5a binding to c5ar1 that is in phase ii clinicals trials for the treatment of covid-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; iph5201, a blocking antibody that is in phase 1 clinical trials targeting the cd39 immunosuppressive pathway; iph5301, an anti-cd73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and iph6101, a nkp46-based nk cell engager for the generation and evaluation of up to two bispecific nk cell engagers. its products in preclinical trials are iph43, an anti-mica/b antibody drug conjugate; anti-siglec-9, an antibody program; iph65, a tetraspecific proprietary antibody; iph25, a checkpoint inhibitor; and iph62 and iph64 programs. innate pharma s.a. has licensing and collaboration agreements with astrazeneca, novo nordisk a/s, sanofi, and orega biotech; and co-development and license agreement with medimmune limited. the company was incorporated in 1999 and is headquartered in marseille, france.
earnings per share
as for profitability, innate pharma has a trailing twelve months eps of €-0.74.
volume
today's last reported volume for innate pharma is 189408 which is 81.06% below its average volume of 175821.
volatility
innate pharma's last week, last month's, and last quarter's current intraday variation average was 0.75%, 0.42%, and 2.41%.
innate pharma's highest amplitude of average volatility was 1.56% (last week), 2.87% (last month), and 2.41% (last quarter).
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, innate pharma's stock is considered to be overbought (>=80).
more news about innate pharma (iph.pa).